MARKET

IPHA

IPHA

Innate Pharma Sa
NASDAQ
1.460
-0.040
-2.67%
Closed 16:00 10/26 EDT
OPEN
1.540
PREV CLOSE
1.500
HIGH
1.540
LOW
1.430
VOLUME
21.88K
TURNOVER
--
52 WEEK HIGH
2.710
52 WEEK LOW
1.170
MARKET CAP
163.08M
P/E (TTM)
-2.5021
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at IPHA last week (1019-1023)?
Weekly Report · 18h ago
Innate Pharma to Participate in the Stifel Healthcare Conference and Jefferies Global Healthcare Conference
Barchart · 6d ago
Innate Pharma Announces Conference Call for Third Quarter 2026 Business and Financial Update
Barchart · 10/20 00:00
Weekly Report: what happened at IPHA last week (1012-1016)?
Weekly Report · 10/19 09:09
Weekly Report: what happened at IPHA last week (1005-1009)?
Weekly Report · 10/12 09:09
Down 25% in 4 Weeks, Here's Why You Should You Buy the Dip in Innate Pharma (IPHA)
NASDAQ · 10/05 12:35
Weekly Report: what happened at IPHA last week (0928-1002)?
Weekly Report · 10/05 09:09
Innate Pharma S.A. - Depositary Receipt Price Target Increased by 27.91% to $8.22
NASDAQ · 10/02 11:44
More
About IPHA
Innate Pharma SA is a France-based biopharmaceutical company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications, and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The Company develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. It works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The Company operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk. It also has a multi-product partnership with AstraZeneca.

Webull offers Innate Pharma SA (ADR) stock information, including NASDAQ: IPHA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IPHA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IPHA stock methods without spending real money on the virtual paper trading platform.